Validation of Promarker®D
in the CANVAS Trial
Predicting renal function decline in Patients with Type 2 diabetes using the Promarker®D test
Chronic kidney disease (CKD) is one of the most serious and underdiagnosed complications of type 2 diabetes. Traditional diagnostic methods (e.g. eGFR and uACR) often fail to detect early risk, leaving clinicians with limited time to intervene before irreversible renal damage occurs.
The prognostic ability of Promarker®D to predict CKD was evaluated in the CANVAS (Canagliflozin Cardiovascular Assessment Study) — one of the largest clinical trials of SGLT2 Inhibitor therapy for type 2 diabetes. The study analyzed 3,568 patients and, in a major breakthrough for improved CKD management, validated the ability of Promarker®D to predict decline in renal function well in advance of standard clinical markers.
